^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
GeneStrat® test

Company:
Biodesix
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
Twitter
GeneStrat® genomic testing is a laboratory test service that determines the presence of somatic genetic variants in circulating nucleic acids (DNA and RNA) from the plasma of patients with lung cancer using ddPCR (Droplet Digital™ Polymerase Chain Reaction. GeneStrat solely reports the presence or absence of certain, limited genomic alterations which may be useful for physicians when considering different therapeutic options. The mutations detected using GeneStrat account for a large proportion of variants found in NSCLC, including EGFR (89% coverage), ALK (78%), ROS1 (88%), RET (99%), KRAS (78%), and BRAF (54%). This includes the EGFR T790M mutation, which is a marker of resistance to anti-EGFR drugs. According to Biodesix, turaround time for the test is 72 hours.
Cancer:
Non Small Cell Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KRAS (KRAS proto-oncogene GTPase), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
PCR